Skip to main content
. 2019 Apr 3;3(7):1084–1091. doi: 10.1182/bloodadvances.2018028035

Table 4.

Non-VAEs in ≥5% of patients

AE No. of patients experiencing AE (% all patients) No. of patients stopping nilotinib because of AE (% of all patients)
Any grade Grade 3-4
Rash 30 (14) 8 (4) 4 (2)
Hepatitis 17 (8) 4 (2) 7 (3)
Pancreatitis 15 (7) 5 (2) 7 (3)
Systemic 12 (5) 2 (1) 3 (1)
Other gastrointestinal (nausea, diarrhea) 10 (5) 0 (0) 1 (<1)